Beta Drugs Limited
Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.
What Beta files
- Others62
- Investor Meet19
- Board Meeting17
- Important15
- Updates13
- Results5
Beta Drugs announced its share transfer books will close from September 24th to 30th for the 21st Annual General Meeting (AGM). Investors should note this book closure period.
BETA has completed the acquisition of 66.09% equity in Nivian Lifesciences, acquiring 10,94,535 shares. This makes Nivian a subsidiary. BETA will now seek NSE listing approval for the share swap arrangements.
Beta Drugs expanded global access with successful Azerbaijan inspection outcomes, boosting CIS market entry, and securing product approvals in the Philippines, establishing early presence. This strengthens international reach and is expected to drive future export revenues.
Beta Drugs clarified its shareholding after a preferential equity issue. Total shares will rise to 1,10,85,872, leading to promoter stake dilution from 64.63% to 59.10%. This move reflects a capital raise.
Beta Drugs clarified details regarding its preferential equity share allotment. The update lists allottees and their resulting stake percentages. This capital-raising exercise supports future company initiatives.